191 related articles for article (PubMed ID: 35833951)
21. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
[TBL] [Abstract][Full Text] [Related]
22. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
23. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non-muscle-invasive Bladder Cancer.
Strandgaard T; Lindskrog SV; Nordentoft I; Christensen E; Birkenkamp-Demtröder K; Andreasen TG; Lamy P; Kjær A; Ranti D; Wang YA; Bieber C; Prip F; Rasmussen J; Steiniche T; Birkbak N; Sfakianos J; Horowitz A; Jensen JB; Dyrskjøt L
Eur Urol; 2022 Dec; 82(6):646-656. PubMed ID: 36210217
[TBL] [Abstract][Full Text] [Related]
24. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
25. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
Neuzillet Y; Leon P; Seisen T; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Mejean A; Pradère B; Roumiguié M; Traxer O; Xylinas E; Fournier G; Roupret M
BJU Int; 2023 May; 131(5):611-616. PubMed ID: 36462164
[TBL] [Abstract][Full Text] [Related]
26. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
27. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
[TBL] [Abstract][Full Text] [Related]
28. The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis.
Packiam VT; Labbate CV; Boorjian SA; Tarrell R; Cheville JC; Avulova S; Sharma V; Tsivian M; Adamic B; Mahmoud M; Werntz RP; Smith ND; Karnes RJ; Tollefson MK; Steinberg GD; Frank I
Urol Oncol; 2021 Jul; 39(7):436.e1-436.e8. PubMed ID: 33485764
[TBL] [Abstract][Full Text] [Related]
29. Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer.
Fadel J; Simonyan D; Fradet V; Lodde M; Lacombe L; Fradet Y; Toren P
Urol Oncol; 2022 Dec; 40(12):539.e1-539.e8. PubMed ID: 36272848
[TBL] [Abstract][Full Text] [Related]
30. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Uhlig A; Strauss A; Seif Amir Hosseini A; Lotz J; Trojan L; Schmid M; Uhlig J
Eur Urol Focus; 2018 Dec; 4(6):924-936. PubMed ID: 28888813
[TBL] [Abstract][Full Text] [Related]
31. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections.
van Puffelen JH; Novakovic B; van Emst L; Kooper D; Zuiverloon TCM; Oldenhof UTH; Witjes JA; Galesloot TE; Vrieling A; Aben KKH; Kiemeney LALM; Oosterwijk E; Netea MG; Boormans JL; van der Heijden AG; Joosten LAB; Vermeulen SH
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36693678
[TBL] [Abstract][Full Text] [Related]
32. A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer.
Sood R; Sharma H; Sharma B; Parekh S; Pujari P; Shewale S
Urol Oncol; 2020 May; 38(5):433-439. PubMed ID: 32037199
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
[TBL] [Abstract][Full Text] [Related]
34. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
Ferro M; Vartolomei MD; Russo GI; Cantiello F; Farhan ARA; Terracciano D; Cimmino A; Di Stasi S; Musi G; Hurle R; Serretta V; Busetto GM; De Berardinis E; Cioffi A; Perdonà S; Borghesi M; Schiavina R; Cozzi G; Almeida GL; Bove P; Lima E; Grimaldi G; Matei DV; Crisan N; Muto M; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Shariat S; Mirone V; Lucarelli G
World J Urol; 2019 Mar; 37(3):507-514. PubMed ID: 29992381
[TBL] [Abstract][Full Text] [Related]
35. Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin.
Fukumoto K; Kikuchi E; Mikami S; Miyajima A; Oya M
BMC Urol; 2016 Jan; 16():5. PubMed ID: 26785916
[TBL] [Abstract][Full Text] [Related]
36. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data.
Tomida R; Miyake M; Minato R; Sawada Y; Matsumura M; Iida K; Hori S; Fukui S; Ohyama C; Miyake H; Hongo F; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Hashine K;
Int J Clin Oncol; 2022 May; 27(5):958-968. PubMed ID: 35142962
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
[TBL] [Abstract][Full Text] [Related]
38. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
39. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.
Brooks NA; Kokorovic A; Xiao L; Matulay JT; Li R; Ranasinghe WKB; Nagaraju S; Shen Y; Gao J; Navai N; Dinney CPN; Grossman HB; Kamat AM
BJU Int; 2021 Jul; 128(1):65-71. PubMed ID: 33210440
[TBL] [Abstract][Full Text] [Related]
40. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]